Literature DB >> 23896008

First polymer "ruthenium-cyclopentadienyl" complex as potential anticancer agent.

Andreia Valente1, Maria Helena Garcia, Fernanda Marques, Yong Miao, Cyril Rousseau, Philippe Zinck.   

Abstract

d-glucose end-capped polylactide ruthenium cyclopentadienyl complex (RuPMC) was newly synthesized by a straightforward method. RuPMC was tested against human MCF7 and MDAMB231 breast and A2780 ovarian adenocarcinoma revealing IC50 values in the micromolar range. A pH dependent hydrolysis is advanced by preliminary UV-visible spectroscopy. Cellular distribution studies showed that RuPMC is predominantly found in the nucleus and in the membrane. Data suggest potential application of RuPMC as a new drug delivery system for Ru(II)Cp compounds.
© 2013.

Entities:  

Keywords:  Anticancer agent; Drug delivery; Polylactide; Ruthenium cyclopentadienyl

Mesh：

Substances：

Year:  2013        PMID： 23896008     DOI： 10.1016/j.jinorgbio.2013.07.002

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN： 0162-0134            Impact factor:   4.155


  6 in total

1.  Metal-containing and related polymers for biomedical applications.

Authors:  Yi Yan; Jiuyang Zhang; Lixia Ren; Chuanbing Tang
Journal:  Chem Soc Rev       Date:  2016-02-24       Impact factor: 54.564

2.  Synthesis and biological assessment of a ruthenium(II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos.

Authors:  Golara Golbaghi; Irène Pitard; Matthieu Lucas; Mohammad Mehdi Haghdoost; Yossef López de Los Santos; Nicolas Doucet; Shunmoogum A Patten; J Thomas Sanderson; Annie Castonguay
Journal:  Eur J Med Chem       Date:  2020-01-03       Impact factor: 6.514

Review 3.  The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.

Authors:  Leli Zeng; Pranav Gupta; Yanglu Chen; Enju Wang; Liangnian Ji; Hui Chao; Zhe-Sheng Chen
Journal:  Chem Soc Rev       Date:  2017-10-02       Impact factor: 54.564

4.  In vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancer.

Authors:  Malgorzata Frik; Alberto Martínez; Benelita T Elie; Oscar Gonzalo; Daniel Ramírez de Mingo; Mercedes Sanaú; Roberto Sánchez-Delgado; Tanmoy Sadhukha; Swayam Prabha; Joe W Ramos; Isabel Marzo; María Contel
Journal:  J Med Chem       Date:  2014-11-26       Impact factor: 7.446

5.  A New Family of Iron(II)-Cyclopentadienyl Compounds Shows Strong Activity Against Colorectal and Triple Negative Breast Cancer Cells.

Authors:  Adhan Pilon; Ana Rita Brás; Leonor Côrte-Real; Fernando Avecilla; Paulo J Costa; Ana Preto; M Helena Garcia; Andreia Valente
Journal:  Molecules       Date:  2020-03-30       Impact factor: 4.411

6.  Biotinylated Polymer-Ruthenium Conjugates: In Vitro and In Vivo Studies in a Triple-Negative Breast Cancer Model.

Authors:  Leonor Côrte-Real; Ana Rita Brás; Adhan Pilon; Nuno Mendes; Ana Sofia Ribeiro; Tiago D Martins; José Paulo S Farinha; M Conceição Oliveira; Fátima Gärtner; M Helena Garcia; Ana Preto; Andreia Valente
Journal:  Pharmaceutics       Date:  2022-06-30       Impact factor: 6.525
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.